FDA Warns of Liver Injury Risk from Menopause Drug

FDA Issues Warning About Veozah, a Treatment for Menopausal Hot Flashes

The Food and Drug Administration (FDA) has issued a warning regarding Veozah, a medication commonly prescribed to alleviate menopausal hot flashes. This decision follows a significant increase in prescriptions and a growing number of reported adverse events.

A Rising Tide of prescriptions and Concerns

Veozah,the brand name for the drug fezolinetant,was granted approval by the FDA in May 2023. Since then, it has become a popular choice for women experiencing the discomfort of hot flashes associated with menopause. Though, reports of potential side effects have also surged alongside it’s rising popularity.

Escalating FDA Warning

The FDA’s warning specifically highlights the potential for severe liver damage associated with Veozah use. The agency advises healthcare professionals to carefully consider the risks and benefits of prescribing Veozah, especially for patients with pre-existing liver conditions. patients currently taking Veozah are urged to promptly consult their healthcare providers about any potential concerns.

Monitoring and Precautions

The FDA emphasizes the importance of close monitoring for patients taking Veozah. Regular liver function tests are recommended to detect any early signs of liver problems. Individuals taking this medication should be alert to any symptoms of liver damage, such as jaundice (yellowing of the skin or eyes), dark urine, and abdominal pain.

FDA Issues Warning on Menopause drug Due to Liver Concerns

The U.S. Food and Drug Administration (FDA) has issued its most serious warning, a black box warning, for Veozah, a drug prescribed to manage menopausal hot flashes.This serious warning stems from a potential risk of severe liver damage associated with the medication.

Black Box Warning: A Signal of Serious Risk

A black box warning is the strictest warning the FDA can issue. Its intended to alert healthcare professionals and patients about perhaps life-threatening risks associated with a drug. In this case,the FDA is highlighting the potential for Veozah to cause liver injury.

what Does This Mean For Patients?

This warning doesn’t mean that everyone taking Veozah will experience liver damage. Though, it’s crucial for both patients and their doctors to be aware of the potential risk. Patients taking Veozah should be monitored closely for signs of liver problems, such as jaundice, abdominal pain, and fatigue. They should report any concerning symptoms to their healthcare provider immediately.

New Treatment Option for Hot Flashes raises Liver Concerns

A new non-hormonal treatment option for hot flashes called veozah was approved in 2023, offering a ray of hope to many women. However, the Food and Drug Administration (FDA) has recently issued a cautionary note, suggesting that women taking Veozah may need more frequent blood tests to monitor for potential liver issues. While Veozah provides relief from the uncomfortable symptoms of hot flashes, the FDA’s recommendation highlights the importance of ongoing monitoring for potential side effects. Women considering Veozah should discuss the risks and benefits with their healthcare providers to make informed decisions about their treatment.

Potential Risk of Liver Damage Associated with Veozah

The U.S. Food and Drug Administration (FDA) issued a warning on Tuesday regarding Veozah, a medication used to treat a specific medical condition. While rare, veozah has been associated with cases of serious liver damage.

Symptoms to watch For

Patients taking Veozah should be vigilant for any signs of liver problems. these can include: * Fatigue * unusual itching * Nausea * Vomiting * Pale stools * Dark urine * Yellowing of the skin or eyes (jaundice) If any of these symptoms develop, it is crucial to contact a healthcare professional immediately and discontinue use of Veozah. “Patients experiencing symptoms such as fatigue, unusual itching, nausea, vomiting, pale stools, dark urine, or yellowing of the skin or eyes should contact their doctor instantly and discontinue use of the medication.” This statement was included in the FDA’s drug safety dialog released on Tuesday.

Prioritizing Patient Safety with Veozah

When it comes to new medications, patient safety is always a top priority. Astellas, the pharmaceuticals company behind the drug Veozah, recently reiterated its commitment to this principle.While affirming that the overall benefits of Veozah outweigh the risks, astellas emphasized the need for open communication and awareness surrounding potential side effects. The company strongly recommends that both patients and healthcare providers remain informed about the possible side effects associated with veozah and the importance of regular laboratory testing. “Astellas emphasized patient safety as their primary concern,” a statement from the company read. [1]: https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due?utm_medium=email&utm_source=govdelivery

FDA Issues Warning on Veozah Due to Potential Liver Injury Risk

The U.S. Food and Drug Administration (FDA) has issued a safety alert concerning Veozah (fezolinetant), a medication used to treat hot flashes associated with menopause.The warning comes after reports of rare but serious liver damage linked to the drug. Veozah, which works by targeting the neurokinin B receptor in the brain to regulate body temperature, has gained popularity as its approval. Though, emerging concerns about potential liver complications have prompted the FDA to take action. The FDA emphasizes that if a patient experiences any signs or symptoms suggesting liver injury while taking Veozah, it’s crucial to stop the medication immediately. This could prevent further damage and allow the liver to potentially recover. The FDA’s warning highlights the importance of being vigilant about potential side effects and seeking prompt medical attention if any concerning symptoms arise. [[1](https://www.drugs.com/fda/safety-communication-fda-adds-warning-rare-occurrence-serious-liver-injury-veozah-fezolinetant-hot-14701.html)]

Key Takeaways

* Veozah is a medication approved to treat hot flashes during menopause.* The FDA issued a warning due to a rare but serious risk of liver injury. * Patients should discontinue Veozah immediately and seek medical attention if they experience any signs of liver problems.

FDA Issues Warning on Veozah Due to Potential Liver Injury Risk

The U.S. Food and Drug Administration (FDA) has issued a safety alert concerning Veozah (fezolinetant),a medication used to treat hot flashes associated with menopause. The warning comes after reports of rare but serious liver damage linked to the drug. Veozah, which works by targeting the neurokinin B receptor in the brain to regulate body temperature, has gained popularity as its approval.Though, emerging concerns about potential liver complications have prompted the FDA to take action. The FDA emphasizes that if a patient experiences any signs or symptoms suggesting liver injury while taking Veozah, it’s crucial to stop the medication immediately. This could prevent further damage and allow the liver to potentially recover. The FDA’s warning highlights the importance of being vigilant about potential side effects and seeking prompt medical attention if any concerning symptoms arise. [[1](https://www.drugs.com/fda/safety-communication-fda-adds-warning-rare-occurrence-serious-liver-injury-veozah-fezolinetant-hot-14701.html)]

Key Takeaways

* Veozah is a medication approved to treat hot flashes during menopause. * The FDA issued a warning due to a rare but serious risk of liver injury. * Patients should discontinue Veozah immediately and seek medical attention if they experience any signs of liver problems.
## FDA Warning on Veozah: A Conversation with Dr. Emily Carter



**[Intro Music]**



**Host:** Welcome back to Archyde Health Insights. Today we’re discussing a recent FDA warning regarding Veozah, a popular new medication for menopausal hot flashes. Joining us is Dr. Emily Carter, a leading endocrinologist and menopause specialist. Dr. Carter, thanks so much for being with us.



**Dr. Carter:** Thank you for having me.



**Host:** Let’s start with teh basics.What exactly is Veozah, and how does it work?



**Dr. Carter:** Veozah, the brand name for the drug fezolinetant, is a non-hormonal medication that was specifically developed to target and reduce the frequency and severity of hot flashes experienced by women during menopause.



**Host:** It seems like Veozah offered hope for millions of women struggling with this common symptom. But now, the FDA has issued a warning about potential liver damage. can you explain what prompted this?



**Dr. Carter:** While Veozah was generally well-tolerated in clinical trials,a small number of cases of serious liver injury have been reported since its wider use began. These cases are rare, but the FDA takes patient safety very seriously and decided to issue a warning to alert both healthcare professionals and patients.



**Host:** What are the symptoms of liver injury that women taking Veozah should be aware of?



**Dr. Carter:** It’s important to emphasize that not everyone taking Veozah will experience these symptoms. but it’s crucial to be vigilant and watch for any signs of liver problems, like fatigue, loss of appetite, nausea, vomiting, dark urine, pale stools, abdominal pain, or yellowing of the skin or eyes, also known as jaundice.



**Host:** What should women who are currently taking Veozah do?



**Dr. Carter:** If you’re experiencing any of these symptoms, you should contact your doctor immediately. Even if you’re not experiencing symptoms,it’s a good idea to schedule a follow-up appointment with your doctor to discuss your individual situation and whether additional monitoring tests are necessary.



**Host:** What about women who are considering starting Veozah?



**Dr. Carter:** The decision to start any medication,especially a new one,should always be made in consultation with your doctor. Discuss your medical history, any other medications you’re taking, and the potential risks and benefits of veozah with them. They can help you make an informed decision based on your individual needs.



**Host:** In its announcement, the FDA has stressed the importance of close monitoring for patients taking Veozah. What kind of monitoring is typically脑海 advisable?



**Dr.Carter:** Typically, regular blood tests are recommended to monitor liver function. The frequency of these tests will likely vary depending on individual factors, but your doctor will determine the best course of action for you.



**Host:** Dr. Carter, thank you so much for shedding light on these important developments and providing valuable guidance for our listeners.



**Dr. Carter:** You’re welcome. Remember, open communication with your healthcare provider is key to managing any health condition and making informed decisions about your treatment.



**Host:** that’s excellent advice. For more details about Veozah and its potential risks, you can visit the FDA’s website at [insert relevant link]. And as always, be sure to consult with your doctor for personalized medical advice.



**[Outro Music]**